{"filings":[{"id":860937,"accession_number":"0001193125-26-257379","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-06-04T20:05:19+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Shareholders approve officer exculpation charter amendment; board adopts updated bylaws at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved exculpation amendment to limit officer liability for monetary damages to full extent under Delaware law.","Shareholders approved elimination of exclusive forum provision from charter.","Board adopted amended bylaws updating advance notice, universal proxy rules, exclusive forum for Securities Act claims.","Elected Dr. David Kupfer and Jan van Heek as directors, each term to 2029.","Ratified Deloitte & Touche as auditor for FY 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":695997,"accession_number":"0001193125-26-241930","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-05-27T20:18:04+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.","Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.","Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.","No obligation to sell any shares; program provides capital-raising flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93984,"accession_number":"0001193125-26-205129","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.","GAAP net loss $125.4M ($2.86/share) vs $3.8M ($0.50) prior year; non-GAAP adjusted net loss $7.3M ($0.17/share).","Cash and equivalents $78.2M at March 31, down from $82.4M at Dec 31; warrant exercise raised net $1.2M in Q1.","Leadership: Appointed Jim O’Connor CBO & General Counsel; President Geoff Race left, remains as consultant.","R&D spend rose to $5.3M from $1.4M on trial costs; G&A $11.4M included $6.6M one-time stock comp charge."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93983,"accession_number":"0001193125-26-143986","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences sets 2026 annual meeting for June 3; proposal deadlines announced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting of stockholders scheduled for June 3, 2026.","Stockholder proposals for proxy inclusion due by April 16, 2026.","Nominations and other business proposals due by April 21, 2026.","All notices must be sent to Minerva's Burlington, MA office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93982,"accession_number":"0001193125-26-140148","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences President resigns; James O'Connor named Chief Business Officer and General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geoffrey Race resigned as President effective March 31, 2026 after 16 years with the company.","Race will serve as consultant from April 15, 2026 to April 14, 2027 at £333/hour (min 35 hrs/month).","James O'Connor appointed Chief Business Officer and General Counsel effective April 21, 2026.","Press release highlights focus on roluperidone for negative symptoms of schizophrenia and planned Phase 3 trial.","Race receives full vesting of outstanding stock options with exercise period extended to January 1, 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106006,"accession_number":"0001193125-26-101074","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Minerva (NERV) Q4 non-GAAP adj loss $7.1M; cash $82.4M; Phase 3 roluperidone on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Non-GAAP adjusted net loss for Q4 2025 was $7.1M ($0.64/sh) vs $4.0M ($0.53/sh) in Q4 2024.","GAAP net loss for Q4 2025 was $283.7M ($25.51/sh), driven by $321.5M non-cash preferred stock and warrant issuance expense.","Cash, cash equivalents and restricted cash at Dec 31, 2025: $82.4M, up from $21.5M at Dec 31, 2024, from $80M private placement.","Phase 3 confirmatory trial of roluperidone for negative symptoms of schizophrenia on track for Q2 2026; topline data expected 2H 2027.","R&D expense for Q4 2025 was $2.2M vs $2.0M for Q4 2024, reflecting higher consultant fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106005,"accession_number":"0001193125-26-034538","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Minerva unveils Phase 3 trial design for roluperidone; planned start Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 trial to enroll 380 patients with negative symptoms of schizophrenia; 1:1 randomization to placebo or 64 mg roluperidone.","Primary endpoint: change from baseline in PANSS Marder negative symptoms factor score (NSFS) at 12 weeks.","After 12 weeks, patients enter 40-week relapse assessment phase; crossover to roluperidone or antipsychotics.","Topline efficacy results expected H2 2027; relapse assessment data expected H2 2028.","Trial initiation (first patient screened) subject to FDA feedback, targeted Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122301,"accession_number":"0001193125-25-328715","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Minerva Neurosciences stockholders approve increase in authorized common shares to 250M and 12.5M new equity plan shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing authorized common shares from 125M to 250M. Votes: 4,917,181 for, 314,773 against.","Approved amendment to 2013 Equity Plan adding 12,500,000 shares for issuance under the plan. Votes: 3,653,490 for, 32,045 against.","Elected Fouzia Laghrissi-Thode and Inderjit Kaul as directors with 3,502,340 and 3,650,817 votes for, respectively.","Approved issuance of common shares upon conversion of Series A Preferred Stock. Votes: 2,909,574 for, 114,818 against.","Ratified Deloitte & Touche as independent auditor for FY2025 with 5,152,013 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122300,"accession_number":"0001193125-25-287048","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.","Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.","Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.","Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.","Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122299,"accession_number":"0001193125-25-245552","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Minerva Neurosciences raises up to $200M to fund Phase 3 trial of roluperidone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: $80M upfront Series A preferred; Tranche A warrants for another $80M (cash exercise), Tranche B warrants for $40M contingent on milestone event.","Proceeds to finance Phase 3 confirmatory trial, NDA resubmission, and U.S. commercial launch readiness for roluperidone in negative symptoms of schizophrenia.","Board to increase by up to three directors designated by Vivo Capital, expected to have schizophrenia trial experience.","Closing expected October 23, 2025; led by Vivo Capital with participation from Janus Henderson, Farallon, and others.","Company notes alignment with FDA on confirmatory trial design announced August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174928,"accession_number":"0001193125-25-057901","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences regains Nasdaq compliance with net income rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel confirmed compliance with Listing Rule 5550(b)(3) (minimum $500K net income from continuing operations).","Company subject to a one-year discretionary monitor; any future deficiency triggers automatic delist process.","Prior deficiencies for Market Value of Listed Securities (<$35M) and Equity Rule are now resolved.","Panel closed the matter; listing on Nasdaq Capital Market continues effective March 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174927,"accession_number":"0001193125-25-005042","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq Panel grants Minerva continued listing subject to equity compliance by March 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company must file disclosure on transactions to meet $2.5M minimum stockholders' equity by 3/31/25.","Must also provide 12-month income projections with underlying assumptions to Panel by same deadline.","Company is working toward compliance but states no assurance of regaining or maintaining listing.","Original deficiency was market value below $35M; now equity compliance is the key condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191891,"accession_number":"0001193125-24-271652","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Minerva Neurosciences annual meeting vote results: directors elected, say-on-pay approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hans Peter Hasler elected with 3,384,409 For, 353,053 Withheld; Dr. Remy Luthringer elected with 3,705,617 For, 31,845 Withheld (1,624,748 broker non-votes each).","Advisory vote on executive compensation passed: 3,631,040 For, 101,614 Against, 4,808 Abstain (1,624,748 broker non-votes).","Ratification of Deloitte & Touche as auditor for FY2024 approved: 5,134,745 For, 160,496 Against, 66,969 Abstain (no broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191890,"accession_number":"0001193125-24-236726","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting notice for MVLS non-compliance; to request hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Second Nasdaq notice for continued non-compliance with $35M minimum Market Value of Listed Securities; delisting determination unless hearing requested.","Company to request Nasdaq Hearings Panel hearing, which will stay suspension/delisting pending outcome.","Panel may grant extension to April 5, 2025; no guarantee of regaining compliance or continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208350,"accession_number":"0001193125-24-219590","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences sets 2024 annual meeting for Dec 5, stockholder deadline Oct 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for December 5, 2024, more than 30 days from 2023 meeting anniversary.","Stockholder proposals and nominations due by close of business on October 1, 2024.","Deadline applies to both Rule 14a-8 proposals and other business or director nominations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226007,"accession_number":"0001193125-24-150357","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jeryl Hilleman resigns from Minerva Neurosciences Board; Audit Committee roles reassigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeryl Hilleman resigns from Board and Audit Committee Chair, effective August 6, 2024.","Jan van Heek appointed as new Audit Committee Chair; Dr. David Kupfer added to committee.","Resignation not due to any disagreement with the Company, management, or Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226006,"accession_number":"0001193125-24-094620","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Minerva Neurosciences receives Nasdaq delisting notice for low market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MVLS below $35M minimum for 31 consecutive business days as of April 10, 2024.","Grace period of 180 days until October 7, 2024 to regain compliance.","To regain compliance, MVLS must be at least $35M for 10 consecutive business days.","Failure to comply may result in delisting from the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245096,"accession_number":"0001193125-24-047110","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for roluperidone; NDA not approved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cited single positive study insufficient; requires at least one additional positive well-controlled trial.","CRL also demands data on co-administration with antipsychotics and clinically meaningful change.","Safety database inadequate: too few subjects on 64 mg for 12+ months.","Minerva will request a meeting with FDA to discuss path forward; CEO expresses disappointment.","Roluperidone was targeting negative symptoms of schizophrenia, an unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279728,"accession_number":"0001193125-23-245615","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Minerva Neurosciences stockholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors David Kupfer and Jan van Heek elected with ~3.25M and ~3.37M votes, respectively.","Equity plan amendment approved to increase authorized shares by 700,000; 3.28M for, 577K against.","Advisory vote on named executive officer compensation passed with 3.74M for, 71K against.","Ratification of Deloitte & Touche as auditor for FY2023 approved with 5.06M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298168,"accession_number":"0001193125-23-176877","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Minerva Neurosciences raises $20M in PIPE at $10/share for roluperidone launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$20M from 1,425,000 shares at $10/share and 575,575 pre-funded warrants at $9.99.","Investors include Boehringer Ingelheim and Federated Hermes Kaufmann Funds; Boehringer gets board observer rights.","Net proceeds to support U.S. regulatory approval, commercialization, and launch of roluperidone for negative schizophrenia symptoms.","Closing expected on or about June 30, 2023, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298167,"accession_number":"0001193125-23-169682","cik":1598646,"company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Minerva Neurosciences regains Nasdaq compliance on minimum market value requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Compliance Notice on June 16, 2023, after MVLS exceeded $35M for 10 consecutive business days.","Previously faced delisting due to non-compliance; hearing before Nasdaq Hearings Panel cancelled.","Company's common stock will continue trading on Nasdaq Capital Market.","Regained compliance resolves listing uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":246454290.38212928,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}